Lgv1 is a research-based biotech company

Our research started from a ten year long study of Long Lived Inviduals (LLIs) selected in different areas of the world.

We have discovered that the protein BPIFB4 is responsible for the production of eNOS (endothelial nitric oxide synthase), which has an antiaging effect on tissues.

The variation of the protein, LAV-BPIFB4, is even more effective than the regular protein, as it has been able to reverse the aging process of tissues and to repair physiologically many mechanisms involved in the vascular and ischemic damages associated to cardiovascular diseases.

These new protein can be adopted for future therapeutic strategies for a great number of diseases.

Lgv1 is your partner to develop innovative biotechnologies having potential industrial applications.